Implementation of the First Available Long-Acting HIV Medication (Cabotegravir/Rilpivirine) Into Routine Clinical Care

Authors

  • Parth Mehra, MS-2, Wissam El Atrouni, M.D., Kelly Robertson, Pharm.D., Megan Herman, Pharm.D., Lisa Clough, M.D.

DOI:

https://doi.org/10.17161/kjm.vol18.24449

Downloads

Published

2025-09-15

Issue

Vol. 18 No. S3 (2025): Supplement 3: Abstracts from the 2025 KUMC Student Research Forum

Section

Abstracts

License

Copyright (c) 2025 Parth Mehra, MS-2, Wissam El Atrouni, M.D., Kelly Robertson, Pharm.D., Megan Herman, Pharm.D., Lisa Clough, M.D.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

All articles in the Kansas Journal of Medicine are licensed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND 4.0). 

 

How to Cite

Parth Mehra. (2025). Implementation of the First Available Long-Acting HIV Medication (Cabotegravir/Rilpivirine) Into Routine Clinical Care. Kansas Journal of Medicine, 18(S3), 26. https://doi.org/10.17161/kjm.vol18.24449